home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

252.86 -5.52 (-2.14%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Got $500? 3 Growth Stocks to Buy That Could Double Your Money ↗

November 20, 2022

Innovative products and services could keep these companies growing.

Via The Motley Fool

3 Top Cannabis Stocks to Buy in November ↗

November 20, 2022

These solid performers are managing to grow revenue in a difficult environment.

Via The Motley Fool

2 Dirt Cheap Growth Stocks to Buy and Hold for Years ↗

November 18, 2022

In the long run, these stocks could deliver great returns.

Via The Motley Fool

Is Axsome Therapeutics Stock a Buy Now? ↗

November 11, 2022

The company seems to be coming into its own.

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

November 10, 2022

Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings:

Via Benzinga

Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance ↗

November 10, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance.

Via Benzinga

Why Shares of Zymeworks Rose 12.18% on Monday ↗

October 31, 2022

The biotech stock's shares may have been pushed by a short squeeze.

Via The Motley Fool

Why Zymeworks Stock Is Soaring Today ↗

October 19, 2022

Investors applauded a major licensing deal with Jazz Pharmaceuticals.

Via The Motley Fool

Jazz Pharmaceuticals' Return On Capital Employed Insights ↗

August 08, 2022

Via Benzinga

Why Axsome Therapeutics Stock Slipped Today ↗

November 07, 2022

Investors traded out of the company following the latest earnings release, but only to a modest degree.

Via The Motley Fool

3 Top Healthcare Stocks to Buy for November ↗

November 04, 2022

Catalysts lie ahead for these promising stocks.

Via The Motley Fool

2 Marijuana Stocks That Are Set for a Comeback ↗

October 28, 2022

Don't overlook these top stocks when investing in the marijuana space.

Via The Motley Fool

Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval ↗

October 26, 2022

A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals...

Via Benzinga

Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline ↗

October 21, 2022

Via Benzinga

Why Is Zymeworks (ZYME) Stock Up Today? ↗

October 19, 2022

Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ).

Via InvestorPlace

Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal ↗

October 19, 2022

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

October 18, 2022

These two durable companies can navigate the market downturn and beyond.

Via The Motley Fool

3 Red-Hot Stocks That Could Continue to Beat the Market ↗

October 13, 2022

Investors are betting on these companies' revenue growth prospects.

Via The Motley Fool

3 Top Marijuana Stocks to Buy for the Long Haul ↗

October 07, 2022

The three have the financial strength to benefit from increased cannabis sales and cannabis therapies.

Via The Motley Fool

3 Stocks Savvy Investors Are Buying Hand Over Fist ↗

October 06, 2022

These high-flying stocks are defying the bear market.

Via The Motley Fool

Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit ↗

September 29, 2022

A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision...

Via Benzinga

UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar ↗

September 29, 2022

Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading.

Via Benzinga

5 Analysts Have This to Say About Jazz Pharmaceuticals ↗

September 21, 2022

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter:

Via Benzinga

7 Top-Rated Biotech Stocks to Buy for Q4 ↗

September 15, 2022

A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

Via InvestorPlace

The Bright Future Of Cannabis Isn’t In Dispensaries - It’s In The Biotech Lab ↗

August 29, 2022

Cannabis businesses offer a lucrative opportunity for investors, but one sector in particular represents untapped potential: cannabinoid pharmaceuticals.

Via Talk Markets

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 18, 2022

Via Benzinga

Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures ↗

August 18, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents...

Via Benzinga

New Drugs in Pipeline for Hypertension, the Silent Global Pandemic

August 10, 2022

Via Investor Brand Network

New Drugs in Pipeline for Hypertension, the Silent Global Pandemic

August 10, 2022

NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill...

Via FinancialNewsMedia

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com